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While neurons in the central nervous system (CNS) have the capacity to regenerate their
axons after injury, they fail to do so, in part because regeneration is limited by growth
inhibitory proteins present in CNS myelin. Myelin-associated glycoprotein (MAG) was
the first myelin-derived growth inhibitory protein identified, and its inhibitory activity was
initially elucidated in 1994 independently by the Filbin lab and the McKerracher lab using
cell-based and biochemical techniques, respectively. Since that time we have gained
a wealth of knowledge concerning the numerous growth inhibitory proteins that are
present in myelin, and we also have dissected many of the neuronal signaling pathways
that act as stop signs for axon regeneration. Here we give an overview of the early
research efforts that led to the identification of myelin-derived growth inhibitory proteins,
and the importance of this family of proteins for understanding neurotrauma and CNS
diseases. We further provide an update on how this knowledge has been translated
towards current clinical studies in regenerative medicine.
Keywords: myelin, myelin-associated glycoprotein, axon regeneration, myelin-derived inhibitors, neurotrauma,
Rho, Nogo
Introduction
Ramon y Cajal (1991), the Spanish neuroscientist who won the Nobel Prize in Medicine in
1906, first described in detail the frustrated growth response of axons injured in the spinal
cord. Cajal observed in 1905 that cut axons first form growth cones similar to those seen in
development of the nervous system, but then retract into round, static bulbs. Until the early
1980s it was assumed that there was a lack of an intrinsic ability of central nervous system
(CNS) neurons to regenerate. Albert Aguayo first showed that CNS axons can regenerate their
injured axons when provided with a peripheral nerve graft (Richardson et al., 1980; David and
Aguayo, 1981). Later, Aguayo showed that regenerated fibers could form synapses and functional
connections, even in adult animals (Keirstead et al., 1985). All of which raised the question: If
CNS neurons were able to regenerate, what was it that was stopping them from doing so after an
injury?
Advances in our understanding of the control of axonal regeneration have followed from
the discovery of growth inhibitory molecules in the CNS, which can signal to block axonal
extension. In its most basic form, CNS injury causes the release of fragmented, disrupted
myelin, and this myelin debris inhibits neurite outgrowth. However, the discovery of this growth
inhibitory activity was not confirmed until the individual myelin proteins responsible were
identified (reviewed by Filbin, 2003). Following the description of these inhibitory proteins, the
identification of their specific neuronal receptor molecules further increased support for the
rather surprising finding that there existed an endogenous neuronal growth inhibition in the CNS.
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Myelin-Derived Inhibitors of Axon Growth
The inhibitors of CNS regeneration can be classified into three
main categories: (1) Myelin-associated inhibitors; (2) Inhibitors
associated with the glial scar that forms after injury; and
(3) Inhibitors of the ‘‘guidance type’’. We focus here on the
myelin-derived inhibitors (see Figure 1). They are important
because myelin is disrupted in both traumatic injury (Richardson
et al., 1982) and neurological diseases includingmultiple sclerosis
(Simons et al., 2014) and neurodegenerative disorders (Bartzokis,
2011).
MAG and Inhibition of Neurite Outgrowth
The first myelin-associated CNS growth inhibitory protein to
be identified was myelin-associated glycoprotein (MAG), and
this activity was discovered independently by Marie Filbin and
collaborators at Hunter College NY (Mukhopadhyay et al.,
1994), and my group and collaborators at McGill University
(McKerracher et al., 1994). The two studies used different
approaches to discern that MAG has growth inhibitory activity, a
surprising finding at the time because MAG is also expressed in
peripheral nerve myelin, peripheral nerves regenerate naturally
after injury, and it had previously been reported that MAG
promoted neurite outgrowth (Johnson et al., 1989; Turnley and
Bartlett, 1998).
My group at McGill was trying to understand why CNS
nerves do not regenerate, and we had characterized changes
in axonal transport and gene expression that were associated
with CNS injury (Fournier and McKerracher, 1995, 1997). To
understand how the environment of the CNS might inhibit
regeneration, we set up a rapid neurite outgrowth assay using
NG108 cells as a screening tool. We teamed up with two other
McGill researchers, biochemist Peter Braun and neuroscientist
Sam David, as we set out to purify the inhibitory proteins
from myelin. We isolated myelin from calf brain and screened
fractionated myelin proteins, seeking those proteins that would
block neurite extension. We found several fractions that blocked
neurite outgrowth, and the major peak of activity co-localized
with the fractions where MAG eluted from the columns
(McKerracher et al., 1994). Using purified recombinant MAG,
we confirmed that MAG completely blocked neurite growth
(McKerracher et al., 1994), and that growth cones retracted
after making even a single filopodial contact (Shibata et al.,
1998).
Simultaneously, and in complementary studies, Marie Filbin
and collaborators Patrick Doherty and Frank Walsh at Guy’s
Hospital in London discovered the growth inhibitory activity of
MAG (Mukhopadhyay et al., 1994). Using a different approach,
Filbin and colleagues were trying to understand how neurons
interact with MAG by plating primary neurons on MAG
substrates. To better simulate the presentation of MAG to
primary neurons, they co-cultured neurons plated onto Chinese
hamster ovary (CHO) cells expressing MAG on their surface.
Surprisingly, they found that neurite outgrowth from cerebellar
neurons was inhibited by MAG, an unexpected finding because
it was initially believed that MAG promoted neurite outgrowth.
When they tested dorsal root ganglion (DRG) neurons, they
found that embryonic DRG neurons grew long neurites on the
MAG-CHO cells, whereas MAG inhibited neurite outgrowth
from neurons isolated from 7 day-old rats (Mukhopadhyay et al.,
1994). These were the first studies to show a developmentally
regulated switch in the neuronal response to myelin-derived
growth inhibitory proteins, with MAG promoting the growth
of embryonic neurons, while blocking axonal extension from
postnatal neurons. Extending this line of studies, Filbin’s
group went on to show that the developmental switch in
growth responsiveness to myelin-MAG was regulated by the
endogenous levels of cyclic AMP (cAMP; Cai et al., 2001). They
identified a developmental decrease in neuronal cAMP levels
and downstream PKA activity that was highly correlated with
the change in neuronal responsiveness to MAG as it became an
inhibitor of neurite outgrowth.
The finding that MAG was a growth inhibitory protein was
both surprising and highly controversial at the time. Part of the
reason for this was that Martin Schwab and collaborators were
engaged in a search for a much larger, 250 kd growth inhibitory
protein in the CNS (Caroni and Schwab, 1988b; Cloned 6 years
after the identification of MAG, this was the myelin-derived
inhibitor now known as Nogo). Immediately after the two papers
reporting MAG as an inhibitor of regeneration (McKerracher
et al., 1994; Mukhopadhyay et al., 1994), Melitta Schachner’s
group, in collaboration with Martin Schwab, studied the myelin
purified fromMAG knockout mice, and determined that growth
inhibitory activity remained (Bartsch et al., 1995). This paper
showed that other inhibitors of neurite outgrowth were present
in the myelin of MAG knockout mice, but it unleashed a
fire-storm of controversy about the importance of MAG in
growth inhibition, a controversy clearly explained in a classic
paper published by Filbin (1996) entitled ‘‘The muddle with
MAG’’. Over the next decade Marie Filbin’s group carefully
characterized the neuronal response to MAG and clarified the
importance and role of MAG in growth inhibition in the
CNS. My group went on to try to understand the neuronal
signaling response to growth inhibitory proteins, focusing on
Rho (Lehmann et al., 1999). Thus it is mainly the large body of
work contributed by Filbin that has carefully characterized the
neuronal response to MAG (for review, see Chaudhry and Filbin,
2007).
MAG in Myelin and Released from Myelin
MAG is a minor constituent of myelin, and it is localized in
mature, compact myelin only in the innermost membrane in
contact with the axon (Trapp, 1990). It is present in both CNS
and peripheral nervous system (PNS) myelin and is thought to
be important for the long-term stabilization of myelinated axons
(Fruttiger et al., 1995). Myelination is a relatively late event in
neurodevelopment and therefore axonal growth cones would
likely never come in contact with myelin, so it is not likely to
play a role in stabilizing neuronal networks, as proposed for the
other growth inhibitory proteins. Only after myelin is damaged
and axons are attempting to regenerate would growth cones
encounter MAG (Tang et al., 2001). In the PNS, where MAG
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FIGURE 1 | A schematic diagram of the protein components involved in the myelin protein-derived inhibition of neurite growth. The oligodendrocyte
derived proteins released from the cell membrane following injury include MAG, Nogo-A (Nogo-66), Oligodendrocyte myelin glycoprotein (OMgp) and Amino-Nogo.
The multicomponent cell surface receptor complexes that are localized to the neuronal cell membrane include the Nogo Receptor 1 (NgR1), Lingo-1, p75NTR, and
TROY, all of which signal to change the activation of Rho (active Rho is indicated by RhoA-GTP). The PirB receptor also binds the myelin-derived inhibitory molecules
but its absolute signaling pathway remains unclear. The C3 transferase enzyme, isolated from Clostridial species, is known to block these Rho activation pathways
and to allow for neurite outgrowth in the face of myelin-derived protein inhibition. (Adapted by permission from Macmillan Publishers Ltd: J. Cereb. Blood Flow
Metab.; Chaudhry and Filbin; 27(6):1096–107, Copyright 2007).
may also be exposed after nerve injury, the high concentration of
laminin is sufficient to override the growth inhibitory property
of MAG (David et al., 1995). By contrast, the CNS does not
contain much laminin or other favorable neuronal growth
substrates.
Filbin made a major discovery about MAG and
myelin-derived growth inhibition that, to date, has been
underappreciated. She discovered that MAG becomes a much
more potent component of CNS growth inhibitory activity
after its release from damaged myelin in a diffusible form
(Tang et al., 1997, 2001). Being a myelin biochemist, Filbin
knew the historical literature on MAG, and the finding more
than 10 years earlier that a soluble form of MAG exists, called
dMAG (Sato et al., 1984). Filbin showed that the dMAG protein
contains the entire extracellular domain of MAG, and it has a
potent growth inhibitory activity. The Filbin group made use
of MAG knockout mice to show that damaged white matter
from normal but not MAG knockout mice inhibited neurite
growth, and that immunodepletion of MAG from the soluble
fraction removed the growth inhibition (Tang et al., 1997,
2001). These results show that MAG is the major inhibitor
of axon growth that is released from damaged myelin and is
present in the soluble fraction that can diffuse in the CNS and
affect neurons that are not in direct contact with myelin debris.
These findings have a major implication for other CNS diseases
where myelin disruption occurs, such as multiple sclerosis,
and could explain why, in the early phase of multiple sclerosis,
neurons can degenerate without obvious evidence of frank
myelin disruption, as soluble, released MAG fragments could
be acting prior to the bulk collapse of myelin (Bjartmar and
Trapp, 2001). Importantly, studies that leveraged knockout
mice lines targeting myelin-associated inhibitor genes, either
individually, or in combination, have left a certain amount of
debate as to the precise role for each of these proteins (Ji et al.,
2008; Cafferty et al., 2010; Lee et al., 2010). Much of the perceived
difficulty relating to these mouse models likely can be ascribed to
differences in the constructs targeting specific genes, the impact
of the absence of these proteins throughout development, as well
as the background of the mice on which they were generated.
If nothing else, these studies have effectively shown that there
is no simple answer to the role of myelin inhibitory proteins in
the regeneration of the CNS for either localized regeneration
or synaptic plasticity or the hope for growth of long axon
tracts.
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Nogo
Despite the importance of MAG and other growth inhibitory
proteins such as other myelin-derived proteins, chemorepulsive
guidance molecules and proteoglycans present in the CNS, a
great deal of recent research activity has focused onNogo. Nogo’s
extensive history in the regeneration literature is, in part, due
to the assertion that it represents the majority of the growth
inhibitory activity first detected by Martin Schwab. In this study
he showed that neurons in culture could grow into peripheral
nerves but not into explanted optic nerves (Schwab and Thoenen,
1985). These early findings led Schwab to hypothesize that a
growth inhibitory activity exists in the CNS, and that a lack of
axon regeneration was not simply due to a lack of appropriate
growth factors.
The Schwab group created a monoclonal antibody, called
IN-1, raised against an inhibitory fraction of myelin, and showed
that it was able to attenuate the inhibitory properties of CNS
myelin in vitro (Caroni and Schwab, 1988a). In adult rats,
injection of the IN-1 antibody directly into the spinal cord
promoted regeneration of axons in the corticospinal tract, and
these axons grew past the lesion into the distal spinal cord
(Schnell and Schwab, 1990). At a Neuroscience meeting in 1999,
the Schwab group presented some peptide sequencing data from
a high molecular weight protein, thought to be the elusive high
molecular weight growth inhibitory protein. The cloning and
sequencing of Nogo followed soon after (Chen et al., 2000;
GrandPré et al., 2000; Prinjha et al., 2000). This Nogo protein was
one of three isoforms (Nogo-A, Nogo-B and Nogo-C) produced
from the Nogo gene by alternative splicing. Nogo-A is expressed
in adult CNS neurons and oligodendrocytes but not in Schwann
cells (GrandPré et al., 2000). Two inhibitory domains of Nogo
have been identified: a 66 amino acid loop (Nogo-66) common
to all three isoforms of Nogo and a unique amino-terminal
region (amino-Nogo) specific to Nogo-A (Prinjha et al., 2000;
Oertle et al., 2003). AlthoughNogo-A has been well characterized
as a myelin-associated inhibitor for axonal regrowth in the
injured CNS, the normal physiological function of Nogo-A
in oligodendrocytes has yet to be fully elucidated. In Nogo
knockout mice, delays in oligodendrocyte differentiation, myelin
sheath formation and axonal caliber growth within the first
postnatal month are observed, and the combined deletion of
Nogo andMAG leads to transient hypomyelination (Pernet et al.,
2008).
OMgp
Oligodendrocyte myelin glycoprotein (OMgp) is a
glycosylphosphatidylinositol (GPI)-anchored CNS myelin
protein that is yet another myelin-derived protein that can
inhibit neurite outgrowth (Kottis et al., 2002; Wang et al.,
2002b). Intriguingly, OMgp is expressed in both neurons and
oligodendrocytes in the CNS (Habib et al., 1998), and the
expression of OMgp correlates with the onset of myelination
(Mikol et al., 1990). OMgp plays a role in mediating the
oligodendrocyte-oligodendrocyte and oligodendrocyte-axonal
membrane interactions at the nodes of Ranvier (Mikol et al.,
1990). Later evidence found a role for OMgp in oligodendroglial-
like cells in preventing collateral sprouting and determining the
spacing of the nodes of Ranvier (Huang et al., 2005).
Neuronal Receptors for Growth Inhibitory
Proteins
The identification of extracellular fragments of myelin-derived
proteins as inhibitors of axonal regeneration in the CNS
supported the notion of the existence of cell surface receptor
molecules that would be involved in transmitting the growth
inhibitory signal. The receptors for the various myelin-derived
growth inhibitory proteins have taken significantly longer to
identify, and new receptors/components are still being added
to the list. One difficulty with identifying potential receptors
is that it appears that MAG, Nogo and OMgp signal through
receptor complexes on the neuronal membrane that may
have a different array of constituents dependent upon the
specific type of neuron being examined. Importantly, however,
it appeared that MAG, Nogo and OMgp all signaled their
inhibitory commands through a receptor complex containing, at
a minimum, the Nogo-66 receptor NgR1 (Fournier et al., 2001;
Domeniconi et al., 2002; Wang et al., 2002b). But given that
NgR1 is a GPI-linked cell surface protein, additional partners
are needed to transmit an intracellular signal inhibiting axonal
outgrowth.
Continuing research into the nature and constituents of
the neuronal receptor for myelin-derived growth inhibitors
has now led to the identification of multiple proteins as
potential participants. Work performed in the laboratory of
Zhigang He identified the neurotrophin receptor molecule
p75NTR as a component of a complex involving NgR1
(Wang et al., 2002a). Yet, other studies failed to identify
an activation of downstream inhibitory Rho signaling if only
NgR1 and p75NTR were expressed, which ultimately led to the
identification of another component of this inhibitory signaling
receptor complex, LINGO-1 (Mi et al., 2004). As the search
for additional components continued, it was abundantly clear
that multiple populations of CNS neurons expressed either
very little or no detectable p75NTR. Research to address
this question led to the identification of the TNF receptor
family member TROY as yet an additional participant in an
inhibitory signal transducing receptor complex (Park et al.,
2005; Shao et al., 2005). Importantly, numerous studies have
made it clear that all of these proteins are involved in signaling
their inhibitory message to Rho. More recently, an additional
transmembrane receptor protein has been identified as a high
affinity binding site for myelin-derived inhibitory proteins, the
paired immunoglobulin receptor B protein (PirB). Originally
identified in the nervous system as an important modulator
of visual cortical developmental plasticity (Syken et al., 2006),
collaborative work between the Shatz and Tessier-Lavigne labs
showed that all threemyelin-derived inhibitorymolecules bind to
PirB with high affinity and it signals to inhibit neurite outgrowth
(Atwal et al., 2008). The linkage between these inhibitory
receptor complexes and CNS plasticity is one that continues to be
explored, especially in the context of managing repair in the CNS.
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Translation to Clinical Studies
Advances in our understanding of the role of growth inhibitory
protein in blocking axon regeneration and functional repair in
the CNS have led to the development of viable drug candidates to
treat neurotrauma. Clinical studies with MAG as drug target to
promote nerve repair have been carried out by GlaxoSmithKline.
They have studied the use of anti-MAG antibodies for potential
efficacy in treating stroke. A humanized monoclonal antibody
to MAG, GSK249320, blocks growth inhibition by MAG. This
antibody was tested in 42 squirrel monkeys +24–72 h after stroke
(Barbay et al., 2015). Trained on a pellet retrieval task, the
monkeys had 30 mg/kg anti-MAG administered intravenously
once weekly for 7 weeks. Treated animals showed a more rapid
recovery of dexterity, with increased performance as early as
3 days after treatment. It is likely too early to be a result of axon
regeneration, suggesting a neuroprotective effect (Barbay et al.,
2015). Nogo receptor signaling to Rho plays an important role
in neuroprotection (Dubreuil et al., 2003). Therefore blocking
MAG inhibitory activity though binding the Nogo receptor likely
accounts for the early recovery by reducing cell death. Further,
mutant mice lacking NgR also recover from stroke better than
controls (Lee et al., 2004).
Overall, MAG and other targets in the growth inhibitory
signaling pathway show promise for translation to clinical
study for treatment of various disorders, from multiple
sclerosis and Alzheimer’s Disease to spinal cord injury
(for review, see Hawryluk et al., 2008; Schwab, 2010; Schmandke
et al., 2014).
Summary
Today it is known that there is a plethora of growth inhibitory
proteins expressed in the CNS, from the myelin-derived growth
inhibitory proteins to chemorepulsive factors that are important
in axonal guidance in development. The role of many of these
proteins is still being elucidated, and it is now clear that
growing axons respond to both ‘‘stop’’ and ‘‘go’’ signals, and
that the preponderance of stop signals in the CNS plays a key
role in preventing repair after traumatic injury. These findings
have led to a new generation of approaches to overcoming
growth inhibition in the CNS to promote regeneration and
functional repair after injury. Marie Filbin’s pioneering work
on MAG has both withstood the test of time and led the
way for clinical advances to treat many different neurological
disorders.
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